Navigation Links
Gene expression test distinguishes between breast cancer patients at high and low risk of late recurrence
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A test that measures the expression levels of 58 genes in oestrogen receptor-positive breast cancers can effectively differentiate between patients who are at higher and lower risk for having their cancer recur elsewhere in the body more than five years after diagnosis, researchers report.

The new findings show that better individual risk prediction for women with these cancers is getting nearer, says study author Prof Michael Gnant from the Medical University of Vienna, Austria.

Prof Gnant reported the findings at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

Metastasis after 5 years of follow-up is an important research issue, particularly in hormone-receptor positive breast cancer, Prof Gnant explains.

"Despite all great progress we have made in the treatment of this most frequent subtype of breast cancer, some patients develop metastasis many years after their initial diagnosis. Extending adjuvant endocrine therapy to prevent this is an option, but comes with substantial side-effects and cost for society, and should therefore be reserved for those patients who really need it. Thus, better defining individual risk for late metastasis is an important medical and scientific need," Prof Gnant says.

The PAM50 Risk of Recurrence (ROR) score used by the researchers in this study directly measures the expression levels of 58 different genes (50 discriminator genes and 8 controls).

Prof Gnant and colleagues performed the PAM50 analysis on 1,478 patients who had taken part in the ABCSG-8 trial, which ran from 1996 to 2009. They found that the PAM50 ROR score provided significant prognostic information in addition to clinical factors with respect to late distant-relapse-free survival.

After 11 years of median follow-up, of patients who were classified by the test as having low risk, 98.7% had not had a late metastasis between 5 and 10 years of follow-up, compared to 91.5% of those with a high PAM50 ROR score. This was true both for node-positive and node-negative disease.

"It makes a huge difference whether a patient looks at an individual risk of 1.3% or 8.5% between years 5 and 10. This is more than six times as much risk. Such important information may well be implemented into individual treatment decisions," Prof Gnant says.

The researchers conclude that the PAM50 ROR score can successfully be used to differentiate patients with respect to their risk for late metastasis, in addition to established clinical and pathological risk factors.

This ability to predict late metastasis may be used in the future to identify patients with endocrine-responsive breast cancer who need or alternatively who can be spared extended adjuvant therapy, they say.

"We have to admit that at this point we cannot prove definitely that we will improve the outcome in patients we have now identified as high risk by extending their adjuvant therapy, but it appears logical that this may be the case. At least as important, if we can define an individual patient reliably as low risk, we can spare her the burden of unnecessary treatment extension," Prof Gnant says.

Commenting on the results, Dr W Fraser Symmans, Professor and Director of Research Operations, Department of Pathology at the University of Texas M.D. Anderson Cancer Center, USA, said they were important for prognostic testing of early breast cancers and for confidently limiting the duration of endocrine therapy to 5 years for women with low-risk disease.

"In the last 6 months it has become clear that three prognostic tests, including the PAM50 ROR score, have similar prognostic utility that holds for up to 15 years after initial diagnosis. It is particularly exciting for the diagnostic community that such newer tests could be offered by pathology laboratories, and might not require centralised testing. I look forward to seeing the results of studies that report the inter-laboratory consistency of these tests for determining the long-term prognosis for early breast cancer patients who received 5 years of adjuvant endocrine therapy," Dr Symmans said.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. McHugh Plastic Surgery & Secret Expressions Med Spa Offer Injection Day Specials
2. Gene-expression signature may signify risk for recurrence, metastasis in prostate cancer
3. Tweaking gene expression to repair lungs
4. Synthetic circuit allows dialing gene expression up or down in human cells
5. Gene expression improves the definition of a breast cancer subtype
6. Gene expression test identifies low-risk thyroid nodules
7. Overexpression of proteins 14-3-3 related to chemotherapy resistance
8. Control of gene expression: Histone occupancy in your genome
9. Changes in gene expression may help explain high blood pressure in pregnancy
10. Gene Distinguishes Early Birds from Night Owls and Helps Predict Time of Death
11. Marker distinguishes more-aggressive from less-aggressive forms of chronic leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... The Aresty ... of corporate finance programs to address the increasingly complex educational needs of today's ... their knowledge of sophisticated corporate finance and will increase their ability to confidently ...
(Date:3/30/2017)... ... March 30, 2017 , ... This morning, ... President Trump expressing their support for an independent Vaccine Safety Commission. Five of ... one medical journalist, will hold a press conference at 9:00 AM Friday, ...
(Date:3/29/2017)... ... 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has recently ... assists dog owners in creating legally-enforceable pet trusts for their canine companions. , ... to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When ...
(Date:3/29/2017)... ... ... Sports Brand EXOUS Bodygear announced today a special sale price for the ... days of March, the price will be only $19.97. The EXOUS Bodygear 65cm ... (regular retail price $19.97). , The special promotional prices are to help individuals get ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or ... teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... Centers & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected ... The Untapped Proton Therapy Market for South Korea ... Proton Therapy plays an important role in delivering comprehensive cancer care ...
(Date:3/29/2017)... 2017  Zynex (OTCQB: ZYXI), an innovative medical technology company ... devices for pain management, stroke rehabilitation, cardiac monitoring and ... Company,s 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 ... Company expects to file its 2016 full year financial ... ...
(Date:3/29/2017)... India , March 29, 2017 According to ... by Detection Type (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal ... Forecast to 2021" published by MarketsandMarkets, the market is expected to reach ... a CAGR of 6.5% from 2016 to 2021. ... ...
Breaking Medicine Technology: